CA
NZ
UK
AU
IND
US
…
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on DMD Digital Health Connections Group Inc (ticker APTOF) is limited, so its precise business activities and financial profile are not clearly documented. Potential long-term growth drivers would be linked to adoption of digital health services and data-driven care models, and investors may find the company attractive if it establishes scalable offerings, sustainable revenue and transparent reporting.
The principal investment risk is the lack of transparent public filings and operating disclosure, which creates material execution, liquidity and financing uncertainty that investors should monitor.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -25.47M | -25.43M | -51.21M | -41.82M | -65.35M |
| Net income | -25.47M | -25.43M | -51.21M | -41.82M | -65.35M |
| Selling general administrative | 13.36M | 11.13M | 15.54M | 14.43M | 19.32M |
| Reconciled depreciation | 0.42M | 0.40M | 0.47M | 0.53M | 0.62M |
| Operating income | -24.72M | -26.26M | -52.36M | -42.60M | -65.45M |
| Interest expense | 0.84M | 0.21M | 0.00M | - | - |
| Interest income | 0.10M | 0.36M | 1.15M | 0.79M | 0.09M |
| Net interest income | -0.74M | 0.15M | 1.15M | 0.79M | 0.09M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 24.72M | 26.26M | 52.36M | 42.60M | 65.45M |
| Total other income expense net | -0.01M | 0.68M | -0.00M | -0.01M | -0.00M |
| Net income from continuing ops | -25.47M | -25.43M | -51.21M | -41.82M | -65.35M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 10.01M | 10.13M | 12.99M | 51.03M | 82.53M |
| Other current assets | 0.14M | 0.57M | 0.60M | 0.26M | 0.13M |
| Total liab | 37.18M | 14.67M | 15.89M | 13.29M | 8.29M |
| Total stockholder equity | -27.17M | -4.54M | -2.90M | 37.74M | 74.24M |
| Capital stock | 459.77M | 457.40M | 444.81M | 437.52M | 437.39M |
| Retained earnings | -566.43M | -540.97M | -515.54M | -464.33M | -422.51M |
| Cash | 0.94M | 6.15M | 9.25M | 36.97M | 39.11M |
| Total current liabilities | 9.31M | 4.46M | 15.27M | 12.28M | 8.17M |
| Net debt | 26.94M | 3.87M | - | - | - |
| Total current assets | 6.45M | 9.53M | 11.89M | 49.52M | 81.74M |
| Short term investments | - | - | 0.00M | 9.99M | 40.01M |
| Long term debt | 27.87M | 10.02M | - | - | - |
| Accounts payable | 2.91M | 1.26M | 3.49M | 3.34M | 1.70M |
| Non currrent assets other | 3.39M | - | - | - | - |
| Non current assets total | 3.57M | 0.60M | 1.09M | 1.51M | 0.79M |
| Capital lease obligations | 0.19M | 0.62M | 1.01M | 1.30M | 0.57M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | 9.99M | 30.09M | -35.00M |
| Net borrowings | 18.55M | 10.00M | 0.00M | - | - |
| Total cash from financing activities | 19.38M | 33.41M | 6.91M | 0.12M | 0.23M |
| Net income | -25.47M | -25.43M | -51.21M | -41.82M | -65.35M |
| Change in cash | -2.61M | -2.54M | -27.72M | -2.14M | -78.28M |
| Begin period cash flow | 6.71M | 9.25M | 36.97M | 39.11M | 117.39M |
| End period cash flow | 4.10M | 6.71M | 9.25M | 36.97M | 39.11M |
| Total cash from operating activities | -21.99M | -35.98M | -44.59M | -32.32M | -43.30M |
| Issuance of capital stock | 0.83M | 23.41M | 6.88M | 0.10M | 0.04M |
| Depreciation | 0.42M | 0.40M | 0.47M | 0.53M | 0.62M |
| Sale purchase of stock | 0.00M | -0.02M | - | - | - |
| Capital expenditures | 0.00M | 0.01M | 0.03M | 0.02M | 0.21M |
| Change in working capital | 2.17M | -11.03M | 2.81M | 4.32M | 1.52M |
| Stock based compensation | 0.48M | 1.06M | 3.65M | 5.21M | 12.95M |
| Other non cash items | 0.41M | -0.38M | -0.31M | -0.57M | 6.97M |
| Free cash flow | -21.99M | -35.98M | -44.62M | -32.35M | -43.52M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.41 1.00% |
41.10 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-0.86 0.16% |
547.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
43.35 4.73% |
959.41 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Dr. William G. Rice Ph.D. | Chairman, President & CEO | 1959 |
| Mr. Fletcher Payne | Senior VP, CFO, Chief Business Officer & Secretary | 1963 |
| Dr. Rafael Bejar M.D., Ph.D. | Senior VP & Chief Medical Officer | 1973 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.29%
Communication Services
+0.51%
Consumer Cyclical
-0.08%
Consumer Defensive
-0.14%
Energy
+1.08%
Financial Services
+0.14%
Financials
-0.06%
Healthcare
+0.51%
Industrials
+0.47%
Real Estate
-0.23%
Technology
+2.03%
Utilities
-0.13%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...